Oscar Health Trading at a Premium: Why Should You Still Buy It?

OSCR has surged 142.5% year-to-date and now trades at 4.65x book value, a premium multiple that leaves little room for execution slips. The rally rests on a sharp operating ramp: Q2 revenue jumped 70% to $4.88 billion, while membership climbed to 2.96 million.

Management is guiding to a 20% revenue CAGR through 2027 and a 5% operating margin next year. The company is also expanding into more than 150 new metropolitan areas, extending its technology-driven platform into fresh markets. Analysts have kept a constructive stance, with earnings estimates revised upward.

Interpretation: the 4.65x book multiple suggests the market has already priced in much of the growth and margin-improvement story. A 5% operating margin target is the figure that must be delivered to justify that valuation, since revenue growth alone no longer differentiates the stock after a 142.5% run.

The classifier flags MOH and CNC as related names, but the source supplies no figures on either, so OSCR's metrics stand alone here.